Indo Borax & Chemicals Limited (NSE:INDOBORAX) disclosed on August 20, 2026 that its board approved a share purchase agreement to acquire 64.26% of Kronox Lab Sciences Limited for an aggregate cash consideration of Rs 246.12 crore, triggering a mandatory open offer under SEBI SAST Regulations.
Key Highlights
- The board approved acquisition of 2,38,44,000 equity shares of Kronox Lab Sciences Limited, representing 64.26% of its share capital, from three promoter-sellers at Rs 103.22 per share under a share purchase agreement.
- Total cash consideration under the SPA amounts to Rs 246,11,77,680, payable by electronic transfer; the per-share price inclusive of transition support consultancy fees is Rs 105.87.
- A mandatory open offer for up to 95,70,000 equity shares, representing approximately 25.79% of Kronox Lab's voting share capital, will be made at Rs 157.27 per share in accordance with SAST Regulations.
- The acquisition is not a related party transaction, requires no governmental or regulatory approvals, and is expected to complete within three months of the public announcement.
About the Company
Indo Borax & Chemicals Limited (NSE:INDOBORAX), headquartered at Nariman Point, Mumbai, manufactures boron-based specialty chemicals and related products. The company is listed on both NSE and BSE (scrip code 524342) and operates in the chemicals and specialty materials sector. Its registered office is at 506, 5th Floor, Tulsiani Chambers, Free Press Journal Marg, Mumbai 400021, with CIN L24100MH1980PLC023177.
Announcement in Detail
Under the board-approved SPA, Indo Borax & Chemicals Limited will acquire 2,38,44,000 equity shares of face value Rs 10 each in Kronox Lab Sciences Limited from its promoters: Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal. The SPA price is Rs 103.22 per share, totalling Rs 246,11,77,680. Zenrock Chemicals Private Limited acts as a person acting in concert with Indo Borax in this transaction.
Since the acquisition gives Indo Borax control and voting rights exceeding 25% of Kronox Lab's share capital, a mandatory open offer under the SEBI SAST Regulations, 2011 is triggered. The open offer is for up to 95,70,000 equity shares at Rs 157.27 per share, determined per SAST norms. Kronox Lab Sciences (NSE:KRONOX, BSE: 544187), incorporated in 2008 and headquartered in Vadodara, Gujarat, manufactures high-purity specialty fine chemicals. Its reported turnover for FY2025-26 was Rs 101.22 crore, against Rs 100.19 crore in FY2024-25 and Rs 89.86 crore in FY2023-24.
Impact on Investors
Investors will note that this transaction involves a cash outflow of Rs 246.12 crore for the SPA alone, with additional capital required if the open offer is fully subscribed at Rs 157.27 per share. The filing shows the acquisition is at board-approval stage only; shareholder, regulatory, or NCLT approvals are not required per the disclosure, and completion is targeted within three months of the public announcement.
Shareholders of Kronox Lab Sciences will observe that the open offer price of Rs 157.27 per share is materially higher than the SPA price of Rs 103.22, as required under SAST Regulations. The disclosed terms indicate that Indo Borax's long-term intent is portfolio diversification into specialty fine chemicals, though no synergy figures or financial projections have been disclosed in the filing.
Sector / Market Context
India's specialty chemicals sector has seen sustained capacity investment, with the industry body CHEMEXCIL and Commerce Ministry data noting rising exports of fine and specialty chemicals in recent years. High-purity specialty fine chemicals, Kronox Lab's core segment, serve pharmaceutical, agrochemical, and industrial end-users, segments that have recorded consistent domestic demand growth according to publicly available industry reports.